Kitov Pharma Ltd. is a clinical-stage company dedicated to developing innovative therapies to combat tumor immune evasion and drug resistance in cancer treatment. Their pipeline includes NT219, a small molecule targeting cancer drug resistance pathways, which is being developed as a monotherapy and combination therapy with cetuximab for advanced solid tumors and head and neck cancer. The company is also working on CM24, a monoclonal antibody blocking CEACAM1, a novel immune checkpoint that supports tumor immune evasion and survival, which is being developed as a combination therapy with anti-PD1 checkpoint inhibitors for non-small cell lung cancer and pancreatic cancer.
Kitov Pharma Ltd.'s ticker is KTOV
The company's shares trade on the NASDAQ stock exchange
They are based in Tel Aviv, Israel
There are 1-10 employees working at Kitov Pharma Ltd.
It is https://kitovpharma.com/
Kitov Pharma Ltd. is in the Healthcare sector
Kitov Pharma Ltd. is in the Biotechnology industry
The following five companies are Kitov Pharma Ltd.'s industry peers: